Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jennifer Leigh Crombie, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, Brown JR, Crombie JL, Davids MS, Fisher DC, Freedman AS, Jacobsen ED, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Jacene H, Park H, Dahi PB, Nieto Y, Joyce R, Chen YB, Shipp MA, Herrera AF, Armand P. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2022 Nov 18. PMID: 36399518.
    Citations:    Fields:    
  2. Sherman AC, Crombie JL, Cheng C, Desjardins M, Zhou G, Ometoruwa O, Rooks R, Senussi Y, McDonough M, Guerrero LI, Kupelian J, Doss-Gollin S, Smolen KK, van Haren SD, Armand P, Levy O, Walt DR, Baden LR, Issa NC. Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies. Open Forum Infect Dis. 2022 Aug; 9(8):ofac417. PMID: 36043177.
    Citations:    
  3. Taranto E, Redd R, Jeter E, McHugh K, Crombie JL, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Odejide OO, Dahi PB, Nieto Y, Joyce RM, Chen YB, Bonjoc KC, Chaudhry A, Herrera AF, Armand P, Merryman RW. Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma. 2022 12; 63(12):2912-2917. PMID: 35938581.
    Citations:    Fields:    Translation:HumansCells
  4. Gouni S, Rosenthal AC, Crombie JL, Ip A, Kamdar MK, Hess B, Feng L, Watson G, Ayers A, Neelapu SS, Khurana A, Lin Y, Iqbal M, Merryman RW, Strati P. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. Blood Adv. 2022 05 10; 6(9):2757-2762. PMID: 35240681; PMCID: PMC9092406.
    Citations: 2     Fields:    Translation:Humans
  5. Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May; 9(5):e327-e339. PMID: 35366963.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  6. Davids MS, Shadman M, Parikh SA, Ujjani C, Crombie JL, Jiang D, Llamas C, Feng D, Lamanna N. A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia. Am J Hematol. 2022 03 01; 97(3):E105-E109. PMID: 34929063.
    Citations: 1     Fields:    Translation:Humans
  7. Evans MG, Crymes A, Crombie JL, Basu SS, Dillon DA, Wong WJ. Monotypic plasmacytoid cells mimicking lymph node malignancy in the setting of COVID-19 recovery. Am J Hematol. 2022 05; 97(5):666-667. PMID: 34779014; PMCID: PMC8646593.
    Citations:    Fields:    Translation:HumansCells
  8. Merryman RW, Redd R, Jeter E, Wong JL, McHugh K, Reynolds C, Nazzaro M, Varden A, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Dahi PB, Nieto Y, Joyce RM, Chen YB, Herrera AF, Armand P, Ritz J. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplant Cell Ther. 2022 01; 28(1):32.e1-32.e10. PMID: 34670169; PMCID: PMC8792205.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  9. Crombie JL, Nastoupil LJ, Redd R, Tang K, Shouse G, Herrera AF, Chow VA, Shadman M, Castaneda Puglianini O, Saucier A, Jacobson CA, Armand P, Simmons G. Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv. 2021 09 28; 5(18):3563-3567. PMID: 34474474; PMCID: PMC8945592.
    Citations:    Fields:    Translation:Humans
  10. Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, Montegaard J, Patterson V, Weinstock M, Crombie JL, Ng SY, Kim AI, Jacobson CA, LaCasce AS, Armand P, Arnason JE, Fisher DC, Brown JR. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021 10; 22(10):1391-1402. PMID: 34534514.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  11. Crombie JL, Sherman AC, Cheng CA, Ryan CE, Zon R, Desjardins M, Baker P, McDonough M, Izaguirre N, Bausk B, Krauss J, Gilboa T, Senussi Y, Walt DR, Davids MS, Brown JR, Armand P, Baden LR, Issa N. Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies. Blood Adv. 2021 08 24; 5(16):3062-3065. PMID: 34387646; PMCID: PMC8362656.
    Citations: 4     Fields:    Translation:HumansCells
  12. Crombie JL, Brown JR. The future of antibody therapy in chronic lymphocytic leukemia. Expert Opin Emerg Drugs. 2021 09; 26(3):323-336. PMID: 34375544.
    Citations: 1     Fields:    Translation:Humans
  13. Crombie J, LaCasce A. The treatment of Burkitt lymphoma in adults. Blood. 2021 02 11; 137(6):743-750. PMID: 33171490.
    Citations: 7     Fields:    Translation:HumansCellsPHPublic Health
  14. Chase ML, Merryman R, Fisher DC, Jacobsen E, LaCasce A, Jacobson C, Freedman A, Davids MS, Brown JR, Jacob A, Armand P, Crombie J. A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leuk Lymphoma. 2021 02; 62(2):478-481. PMID: 33236969.
    Citations:    Fields:    Translation:Humans
  15. Crombie JL, Armand P. Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm. J Clin Oncol. 2020 10 20; 38(30):3565-3574. PMID: 32813609.
    Citations: 4     Fields:    Translation:Humans
  16. Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867. PMID: 32126141; PMCID: PMC7065472.
    Citations: 10     Fields:    Translation:Humans
  17. Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, Herrera AF, Dahi P, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Bsat J, Patel SS, Ritz J, Rodig SJ, Shipp MA, Chen YB, Joyce RM. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 01 14; 4(1):122-126. PMID: 31917843; PMCID: PMC6960482.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  18. Crombie JL, Armand P. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment. Surg Oncol Clin N Am. 2020 Jan; 29(1):115-125. PMID: 31757308.
    Citations: 2     Fields:    Translation:Humans
  19. Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, Montegaard J, Patterson V, Jacobson CA, Jacobsen ED, LaCasce AS, Arnason JE, Armand P, Fisher DC, Brown JR, Davids MS. Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32. PMID: 31723987.
    Citations:    
  20. Crombie J. Classifying DLBCL Subtypes for Optimal Treatment. Oncology (Williston Park). 2019 Oct 28; 33(10). PMID: 31661151.
    Citations: 2     Fields:    Translation:Humans
  21. Chiappella A, Crombie J, Guidetti A, Vitolo U, Armand P, Corradini P. Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes? Hemasphere. 2019 Oct; 3(5):e284. PMID: 31942539; PMCID: PMC6919463.
    Citations: 3     
  22. Crombie JL, Venkateswaran R, Kim AS, Vaidya A, Fisher DC. Bad to the Bone. N Engl J Med. 2019 Jul 25; 381(4):e9. PMID: 31340097.
    Citations:    Fields:    Translation:HumansCells
  23. Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, Chen YB, Abramson J, Crombie J, Armand P, Nayak L, Panzini C, Riley LS, Gallagher K, Maus MV. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019 09 12; 134(11):860-866. PMID: 31320380; PMCID: PMC7022436.
    Citations: 57     Fields:    Translation:HumansCells
  24. Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Aug; 6(8):e419-e428. PMID: 31208944; PMCID: PMC7036668.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  25. Crombie JL, Armand P. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment. Hematol Oncol Clin North Am. 2019 08; 33(4):575-585. PMID: 31229155.
    Citations: 7     Fields:    Translation:Humans
  26. Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29. PMID: 30952672; PMCID: PMC6609955.
    Citations: 42     Fields:    Translation:HumansCTClinical Trials
  27. Crombie JL, LaCasce AS. Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders. Front Oncol. 2019; 9:109. PMID: 30899698; PMCID: PMC6416204.
    Citations: 26     
  28. Crombie J, Armand P. The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders. Curr Hematol Malig Rep. 2019 02; 14(1):11-21. PMID: 30811017.
    Citations: 2     Fields:    Translation:Humans
  29. Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA, Secrist JP, Drew L, Schuller AG, Cidado J, Letai A, Weinstock DM. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 2019 02 07; 133(6):566-575. PMID: 30498064; PMCID: PMC6367646.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  30. Crombie JL, LaCasce AS. Current considerations in AYA Hodgkin lymphoma. Br J Haematol. 2019 01; 184(1):72-81. PMID: 30460695; PMCID: PMC6310106.
    Citations: 8     Fields:    Translation:Humans
  31. Craig JW, Mina MJ, Crombie JL, LaCasce AS, Weinstock DM, Pinkus GS, Pozdnyakova O. Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. PLoS One. 2018; 13(7):e0199708. PMID: 30020951.
    Citations: 1     Fields:    Translation:Humans
  32. Crombie J, Davids MS. IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017 Dec; 92(12):1393-1397. PMID: 28589701; PMCID: PMC5675754.
    Citations: 7     Fields:    Translation:Humans
  33. Crombie J, Davids MS. Venetoclax for the treatment of patients with chronic lymphocytic leukemia. Future Oncol. 2017 Jun; 13(14):1223-1232. PMID: 28492339.
    Citations: 3     Fields:    Translation:Humans
  34. Crombie J, Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP, Glotzbecker B. Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. Biol Blood Marrow Transplant. 2017 01; 23(1):113-118. PMID: 27789360.
    Citations: 2     Fields:    Translation:Humans
  35. Ravi D, Bhalla S, Gartenhaus RB, Crombie J, Kandela I, Sharma J, Mazar A, Evens AM. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models. Clin Cancer Res. 2014 Dec 01; 20(23):6023-33. PMID: 25316819.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  36. Crombie J, Greenlaw S, Fenner J, Lyle S, Wiss K. Loose anagen hair syndrome in two patients with epidermolysis bullosa simplex, Dowling-Meara type. J Am Acad Dermatol. 2012 Sep; 67(3):e120-1. PMID: 22890742.
    Citations: 1     Fields:    Translation:Humans
  37. Khan MA, Farkhondeh M, Crombie J, Jacobson L, Kaneki M, Martyn JA. Lipopolysaccharide upregulates a7 acetylcholine receptors: stimulation with GTS-21 mitigates growth arrest of macrophages and improves survival in burned mice. Shock. 2012 Aug; 38(2):213-9. PMID: 22683726.
    Citations: 21     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Crombie's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (170)
Explore
_
Co-Authors (57)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.